Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Slides:

Advertisements

Similar presentations

Expert Perspectives on New Treatment Options for Parkinson Disease Psychosis.

Advertisements

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Nurse View.

Advances in Managing Inhibitors in Patients With Hemophilia A

Essential Updates in Atopic Dermatitis:

Advanced NSCLC Without Actionable Mutations

Goals of Therapy for Patients With UC

Progression After Cancer Immunotherapy in Advanced NSCLC

REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design

PCP Perspectives Clinical Considerations in Hyperkalemia

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Atopic Dermatitis Treatment Landscape

Updates in Management of Atopic Dermatitis From Real Patient Cases

Atopic Dermatitis Treatment Landscape

Program Goals. Program Goals What is Atopic Dermatitis?

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Chronic Idiopathic Urticaria

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

Expert Tips for Tackling Atopic Dermatitis in Pediatric Practice

Translating Atopic Dermatitis

HCV Protease Inhibitors in Clinical Practice

Postpartum Depression

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Understanding PAD.

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

EHL Technologies in Hemophilia Care

Gene Therapy: Past, Present, and Future

Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.

Emerging Atopic Dermatitis Treatments:

Navigating New Oral Treatment Algorithms in CLL

Tackling Atopic Dermatitis

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Program Goals Overview Glatiramer Acetate 3 Times a Week.

CGRP Antibodies in Migraine

Advancing the Treatment of IBD With Biologics

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

Management of Systematic Lupus Erythematosus

The Evolving Treatment Landscape in Atopic Dermatitis

Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Maintenance Therapy in Advanced Ovarian Cancer

Advances in Severe Asthma Management

Tackling Schizophrenia With Your Patients

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Guide to Atopic Dermatitis

Atopic Dermatitis in the Pediatric Practice

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

HCV Protease Inhibitors in Clinical Practice

The Changing Field of Melanoma: Ipilimumab.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Add-On Therapy to Insulin in T1DM Management

Update on the Management of Atopic Dermatitis

Communicating With Your Patients About Major Depressive Disorder

Improving Adherence to Antiplatelet Therapy After an ACS Event

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Program Goal. Program Goal Disclaimer Overview.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Educational Objectives

AMD Therapy: Where Are We Now and Where Are We Going?

Checkpoint Inhibitors in First-Line Advanced NSCLC

PAH Pathways: What Do the Data Tell Us?”

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pathophysiologic Targets of Allergic Asthma

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Presentation transcript:

Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion

Background

Case #1: Initial Presentation

Case #1: Response to Treatment With Dupilumab

Case #1: Response to Treatment With Dupilumab (cont)

Case #1: Response to Treatment With Dupilumab (cont)

Approach to the Patient With Moderate to Severe AD

When to Initiate Systemic Therapy

Factors Influencing Selection of a Systemic Therapy

Dupilumab in AD: SOLO1 and SOLO2

Dupilumab in AD: Long-Term Efficacy

Dupilumab Plus TCS in AD: CHRONOS

Effect of Dupilumab on Pruritus and QoL

Case #2: Initial Presentation

Case #2: Response to Treatment With Dupilumab

Considerations in Using Dupilumab in Clinical Practice

Managing Treatment-Related Adverse Events

Looking Ahead: Investigational Agents for AD

Conclusions

Abbreviations